OncoPharm

Latest Episodes:

Zanubrutinib Nov 21, 2019

Show notes

BTK-targeting therapy approved again! Zanubrutinib approved for Mantle Cell Lymphoma (2nd line) - how does it compare to ibrutinib and acalabrutinib?

Immunotherapy Interactions Nov 14, 2019

Show notes

Examining the effects of antibiotics, corticosteroids (6:45), and cannabis (12:05) on immunotherapy effectiveness.

Data Dive Into NK-1 Antagonists & Carboplatin Nov 07, 2019

Show notes

ASCO's updated 2017 antiemetic guidelines recommend NK-1 antagonists to prevent CINV with standard Q 3 week carboplatin (i.e. AUC 5-6), but how good are the data to support that? We dive into the supporting data.

Carboplatin Oct 31, 2019

Show notes

The basic must-know information for carboplatin, for students, residents, or anyone looking for a refresher.

ADAM VTE & Ibrutinib CV Toxicity Oct 24, 2019

Show notes

ADAM VTE (apixaban for cancer-associated VTE) results have been published - let's talk about it. Also, what are the implications of long term ibrutinib on CV health? A new Blood paper offers some possible answers.

To Rechallenge, Or Not To Rechallenge Oct 17, 2019

Show notes

Weighing the risks & benefits of immunotherapy rechallenge in patients with a prior immune-related adverse event (irAE). Reference: https://www.ncbi.nlm.nih.gov/pubmed/31461381

CASPIAN Oct 10, 2019

Show notes

Reviewing the recent Lancet publication of CASPIAN (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext) --> durvalumab + chemo in extensive stage small cell lung cancer.

ESMO 2019 Oct 03, 2019

Show notes

Recapping updates from ESMO 2019. Topics include FLAURA (osimertinib), 5-year OS analyses of immunotherapy in metastatic NSCLC & melanoma, EGFR/BRAF/MEK inhibition in BRAF-V600E colorectal cancer, PARP inhibitors in ovarian cancer, and a possible cabazitaxel comeback.

Danorubicin 90 mg/m2 (AML induction) Sep 24, 2019

Show notes

The Landmarks in #Oncopharm series returns on the 10-year anniversary of this landmark paper (https://www.nejm.org/doi/10.1056/NEJMoa0904544) comparing daunorubicin 90 mg/m2 vs. 45 mg/m2 for AML induction.

New FDA approved indications for lenvatinib, pembro, and apalutamide Sep 19, 2019

Show notes

Discussion of FDA's approval of lenvatinib & pembrolizumab for endometrial cancer followed by a comparison of TITAN v. ENZAMET prompted by apalutamide's latest approval.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected